Insight Molecular Diagnostics Inc. (IMDX): Nasdaq/NYSE listing notice — Oncocyte applies to transfer Nasdaq listing to Capital Market to cure bid price deficiency

Insight Molecular Diagnostics Inc.

Applied on Jan 24, 2023 to transfer listing from Nasdaq Global Market to Nasdaq Capital Market.
Transfer expected to allow additional 180-day compliance period for minimum bid price requirement.
Common stock to continue trading under symbol "OCX" after transfer.
Previously received Nasdaq deficiency notice on Aug 9, 2022 for bid price below $1.00 for 30 consecutive days.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

Insight Molecular Diagnostics Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5450(a)(1), 5810(c)(3)(A)(ii)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5450(a)(1), 5810(c)(3)(A)(ii)

Exact text from the filing

August 9, 2022 indicating that Nasdaq had determined that the Company no longer meets the minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1), as the minimum closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. The Notice provided that the Company may consider applying to transfer the listing of the Company’s common stock to The Nasdaq Capital Market, subject to the Company submitting an online transfer application, paying the requisite fee, satisfying such market’s continued listing requirement for the market value of

View on SEC.gov

Browse all listing & compliance notices →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-002918

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.